101 related articles for article (PubMed ID: 15757441)
21. Biologic and immunologic therapy of ovarian cancer.
Bookman MA; Berek JS
Hematol Oncol Clin North Am; 1992 Aug; 6(4):941-65. PubMed ID: 1500395
[TBL] [Abstract][Full Text] [Related]
22. Molecular targeting and gene delivery in bladder cancer therapy.
Voutsinas GE; Stravopodis DJ
J BUON; 2009 Sep; 14 Suppl 1():S69-78. PubMed ID: 19785072
[TBL] [Abstract][Full Text] [Related]
23. Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
Dizon DS
Am J Clin Oncol; 2013 Oct; 36(5):519-25. PubMed ID: 21552100
[TBL] [Abstract][Full Text] [Related]
24. Discovery and validation of new molecular targets for ovarian cancer.
Hu XF; Xing PX
Curr Opin Mol Ther; 2003 Dec; 5(6):625-30. PubMed ID: 14755889
[TBL] [Abstract][Full Text] [Related]
25. Biologic therapy in the management of refractory ovarian cancer.
Bookman MA
Gynecol Oncol; 1993 Oct; 51(1):113-26. PubMed ID: 8244165
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies.
Nicodemus CF; Schultes BC; Hamilton BL
Expert Rev Vaccines; 2002 Jun; 1(1):35-48. PubMed ID: 12908511
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
Berek JS
Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
[TBL] [Abstract][Full Text] [Related]
28. The immunobiology and immunotherapy of ovarian cancer.
Bookman MA; Bast RC
Semin Oncol; 1991 Jun; 18(3):270-91. PubMed ID: 1710393
[TBL] [Abstract][Full Text] [Related]
29. A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.
Winer I; Buckanovich RJ
Gynecol Oncol; 2010 Mar; 116(3):578-9. PubMed ID: 19897232
[No Abstract] [Full Text] [Related]
30. Technology evaluation: Matuzumab, Merck KGaA.
Kim T
Curr Opin Mol Ther; 2004 Feb; 6(1):96-103. PubMed ID: 15011787
[TBL] [Abstract][Full Text] [Related]
31. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Pietragalla A; Duranti S; Daniele G; Nero C; Ciccarone F; Lorusso D; Fagotti A; Scambia G
Expert Opin Investig Drugs; 2021 Feb; 30(2):103-110. PubMed ID: 33423551
[No Abstract] [Full Text] [Related]
32. Abagovomab for ovarian cancer.
Pfisterer J; Harter P; Simonelli C; Peters M; Berek J; Sabbatini P; du Bois A
Expert Opin Biol Ther; 2011 Mar; 11(3):395-403. PubMed ID: 21241213
[TBL] [Abstract][Full Text] [Related]
33. Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001.
Foon KA; Bhattacharya-Chatterjee M
Clin Cancer Res; 2001 May; 7(5):1112-5. PubMed ID: 11350872
[No Abstract] [Full Text] [Related]
34. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
[TBL] [Abstract][Full Text] [Related]
35. New perspectives in ovarian cancer treatment.
Schmid BC; Oehler MK
Maturitas; 2014 Feb; 77(2):128-36. PubMed ID: 24380827
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies in gynecological cancer: a critical point of view.
Bellati F; Napoletano C; Gasparri ML; Visconti V; Zizzari IG; Ruscito I; Caccetta J; Rughetti A; Benedetti-Panici P; Nuti M
Clin Dev Immunol; 2011; 2011():890758. PubMed ID: 22235224
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies in oncology therapeutics: present and future indications.
Bhutani D; Vaishampayan UN
Expert Opin Biol Ther; 2013 Feb; 13(2):269-82. PubMed ID: 23286740
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy for epithelial ovarian cancer: current status and future prospects.
See HT; Kavanagh JJ; Hu W; Bast RC
Int J Gynecol Cancer; 2003; 13(6):701-34. PubMed ID: 14675307
[TBL] [Abstract][Full Text] [Related]
39. [The prospect of biologic therapy in ovarian cancer].
Qian HN
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):386-8. PubMed ID: 8001411
[No Abstract] [Full Text] [Related]
40. Antibody-based cancer drugs: developing antibody therapeutic approaches to deliver individualized cancer drugs.
Kalland T
IDrugs; 2005 May; 8(5):364-5. PubMed ID: 15883910
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
